A Short Review on Obeticholic Acid: An Effective Modulator of Farnesoid X Receptor

被引:0
|
作者
Narayanan, Anila Kutty [1 ]
Surendran, Sudhindran [1 ]
Balakrishnan, Dinesh [1 ]
Gopalakrishnan, Unnikrishnan [1 ]
Malick, Shweta [1 ]
Valsan, Arun [2 ]
Philips, Abby Cyriac [3 ]
Watson, Christopher [4 ]
机构
[1] Amrita Univ, Amrita Inst Med Sci & Res Ctr, Dept Gastrointestinal Surg & Solid Organ Transplan, Kochi 682041, Kerala, India
[2] Amrita Univ, Amrita Inst Med Sci & Res Ctr, Dept Gastroenterol & Hepatol, Kochi 682041, Kerala, India
[3] Rajagiri Hosp, Liver Inst, Dept Clin & Translat Hepatol, Aluva, Kerala, India
[4] Addenbrookes Hosp, Cambridge Univ Hosp NHS Fdn Trust, Cambridge CB2 OQQ, England
关键词
FXR; Liver metabolism; Bile acids; Obeticholic acid; FXR agonist; PRIMARY BILIARY CHOLANGITIS; NONALCOHOLIC STEATOHEPATITIS; LIVER; METABOLISM; EXPRESSION; FXR; MULTICENTER; ACTIVATION; EFFICACY; AGONIST;
D O I
10.2174/0127724328239536230919070001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Farnesoid X receptor (FXR) was identified as an orphan nuclear receptor resembling the steroid receptor in the late '90s. Activation of FXR is a crucial step in many physiological functions of the liver. A vital role of FXR is impacting the amount of bile acids in the hepatocytes, which it performs by reducing bile acid synthesis, stimulating the bile salt export pump, and inhibiting its enterohepatic circulation, thus protecting the hepatocytes against the toxic accumulation of bile acids. Furthermore, FXR mediates bile acid biotransformation in the intestine, liver regeneration, glucose hemostasis, and lipid metabolism. In this review, we first discuss the mechanisms of the disparate pleiotropic actions of FXR agonists. We then delve into the pharmacokinetics of Obeticholic acid (OCA), the first-in-class selective, potent FXR agonist. We additionally discuss the clinical journey of OCA in humans, its current evidence in various human diseases, and its plausible roles in the future.
引用
收藏
页码:225 / 233
页数:9
相关论文
共 50 条
  • [21] The Effects of Obeticholic Acid, a Farnesoid X Receptor Agonist, in Patients With Chronic Diarrhea Secondary to Crohn's Ileal Disease
    Nolan, Jonathan D.
    Vassie, Claire
    Johnston, Ian M.
    Dew, Tracy
    Shapiro, David
    Walters, Julian R.
    GASTROENTEROLOGY, 2014, 146 (05) : S797 - S797
  • [22] Obeticholic acid, a farnesoid-X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats
    Verbeke, Len D.
    Farre, Ricard
    Trebicka, Jonel
    Komuta, Mina
    Roskams, Tania
    Klein, Sabine
    Vander Elst, Ingrid
    Windmolders, Petra
    Vanuytsel, Tim
    Nevens, Frederik
    Laleman, Wim
    HEPATOLOGY, 2013, 58 : 294A - 295A
  • [23] The First New Trials for Primary Biliary Cirrhosis in a Decade: An International Program Evaluating the Farnesoid X Receptor Agonist Obeticholic Acid
    Kowdley, Kris y
    Nevens, Frederik
    Andreone, Pietro
    Luketic, Velimir A.
    Shah, Hemant
    Pencek, Richard
    Marmon, Tonya K.
    Shapiro, David
    GASTROENTEROLOGY, 2015, 148 (04) : S991 - S992
  • [24] Farnesoid X receptor modulators: a patent review
    Crawley, Matthew Lantz
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (08) : 1047 - 1057
  • [25] Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model
    P. Comeglio
    S. Filippi
    E. Sarchielli
    A. Morelli
    I. Cellai
    C. Corno
    L. Adorini
    G. B. Vannelli
    M. Maggi
    L. Vignozzi
    Journal of Endocrinological Investigation, 2019, 42 : 951 - 965
  • [26] The Bile Acid Sensor Farnesoid X Receptor Is a Modulator of Liver Immunity in a Rodent Model of Acute Hepatitis
    Mencarelli, Andrea
    Renga, Barbara
    Migliorati, Marco
    Cipriani, Sabrina
    Distrutti, Eleonora
    Santucci, Luca
    Fiorucci, Stefano
    JOURNAL OF IMMUNOLOGY, 2009, 183 (10): : 6657 - 6666
  • [27] Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
    Mudaliar, Sunder
    Henry, Robert R.
    Sanyal, Arun J.
    Morrow, Linda
    Marschall, Hanns-Ulrich
    Kipnes, Mark
    Adorini, Luciano
    Sciacca, Cathi I.
    Clopton, Paul
    Castelloe, Erin
    Dillon, Paul
    Pruzanski, Mark
    Shapiro, David
    GASTROENTEROLOGY, 2013, 145 (03) : 574 - +
  • [28] Therapeutic effects of the selective farnesoid X receptor agonist obeticholic acid in a monocrotaline-induced pulmonary hypertension rat model
    Comeglio, P.
    Filippi, S.
    Sarchielli, E.
    Morelli, A.
    Cellai, I.
    Corno, C.
    Adorini, L.
    Vannelli, G. B.
    Maggi, M.
    Vignozzi, L.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2019, 42 (08) : 951 - 965
  • [29] Farnesoid X Receptor Agonists Obeticholic Acid and Chenodeoxycholic Acid Increase Bile Acid Efflux in Sandwich-Cultured Human Hepatocytes: Functional Evidence and Mechanisms
    Guo, Cen
    LaCerte, Carl
    Edwards, Jeffrey E.
    Brouwer, Kenneth R.
    Brouwer, Kim L. R.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2018, 365 (02): : 413 - 421
  • [30] Suppression of Lung Oxidative Stress, Inflammation, and Fibrosis following Nitrogen Mustard Exposure by the Selective Farnesoid X Receptor Agonist Obeticholic Acid
    Meshanni, Jaclynn A.
    Lee, Jordan M.
    Vayas, Kinal N.
    Sun, Rachel
    Jiang, Chenghui
    Guo, Grace L.
    Gow, Andrew J.
    Laskin, Jeffrey D.
    Laskin, Debra L.
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2024, 388 (02): : 586 - 595